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Abstract
Sickle cell disease can lead to hepatic com-
plications ranging from acute hepatic crises to
chronic liver disease including intrahepatic
cholestasis, and iron overload. Although
uncommon, intrahepatic cholestasis may be
severe and medical treatment of this complica-
tion is often ineffective.  We report a case of a
37 year-old male patient with sickle cell ane-
mia, who developed liver failure and under-
went successful orthotopic liver transplanta-
tion.  Both pre and post-operatively, he was
maintained on red cell transfusions. He
remains stable with improved liver function 42
months post transplant. The role for orthotopic
liver transplantation is not well defined in
patients with sickle cell disease, and the expe-
rience remains limited. Although considerable
challenges of post-transplant graft complica-
tions remain, orthotopic liver transplantation
should be considered as a treatment option for
sickle cell disease patients with end-stage liver
disease who have progressed despite conven-
tional medical therapy. An extended period of
red cell transfusion support may lessen the
post-operative complications.    
Introduction
Sickle cell disease (SCD) is an inherited
disorder of hemoglobin (HbS) leading to com-
plications in multiple organ systems. Many
complications are due to either recurrent vaso-
occlusion or chronic hemolysis. Frequently
observed manifestations of hepatic and biliary
tract disease in sickle cell disease patients
include vaso-occlusion of hepatic sinusoids
due to the sickling process, hemosiderosis
from chronic transfusions, viral hepatitis, and
cholelithiasis due to chronic hemolysis.1 In
many patients the cause of liver dysfunction is
multi-factorial.
Acute vaso-occlusion is a common event
resulting from polymerization of deoxygenated
HbS leading to decreased pliability of red blood
cell (RBC) membrane leading to sickle shaped
cells, and increasing the adhesiveness of the
RBC membrane to the endothelium of small
vessels. When sickling occurs in the bone,
these changes result in microvascular occlu-
sions that cause ischemia which manifest as
vaso-occlusive pain crises. In the liver, vaso-
occlusion of sickled RBCs occurs in the hepat-
ic sinusoids, perhaps due to low oxygen ten-
sion.1 The obstructed hepatic sinusoids gener-
ate hepatic congestion leading to
hepatomegaly and hepatocyte necrosis. In
addition, Kupffer cell hypertrophy from
increased phagocytosis of the sickled RBCs
contributes to further sinusoidal obstruction.2
This phenomenon of sickle RBC induced sinu-
soidal obstruction has been termed sickle cell
hepatopathy.1,3,4 Sinusoidal congestion and
ischemic necrosis may lead to cirrhosis. In one
study by Traina et al., among 20 SCD patients
with liver dysfunction who underwent liver
biopsy 19 patients demonstrated sickle cell
hepatopathy from intra-sinusoidal congestion
and vaso-occlusion.1
Congestion of hepatic sinusoids may mani-
fest as a transient acute hepatic crisis associ-
ated with right upper quadrant pain, jaundice,
fever, leukocytosis, increased serum amino-
transferases and elevated bilirubin.3 This form
of sickle cell crisis often resolves without clin-
ical consequences. However, rarely the seques-
tration of sickle cells in the hepatic sinusoids
may lead to more severe and potentially fatal
sickle cell intrahepatic cholestasis (SCIC),
which usually presents as acute hepatic failure
from local ischemia.3,5,6 Untreated SCIC has
been associated with a mortality rate of up to
40%.6 While treatment with red cell transfu-
sions improves survival over supportive man-
agement alone, it is often ineffective with a
mortality of 17% in chronic intrahepatic
cholestasis.6,7 The role for orthotopic liver
transplant (OLT) in patients with SCD and
liver disease is not well defined. There have
only been several cases of OLT for sickle cell
disease patients with liver failure. We describe
a case of a patient with sickle cell anemia and
end-stage liver disease from sickle cell
cholestasis who underwent a successful OLT
and was maintained on perioperative transfu-
sions with a long-term survival.  
Case Report
Our patient is a 37 year old African
American male with homozygous sickle cell
disease whose course included intermittent
vaso-occlusive crises resulting in 1-2 hospital-
izations per year. He has a history of cholecys-
tectomy in 1991 and hospitalizations for acute
pulmonary infiltrates in 1992 and 1998. His
estimated RBC transfusion burden was ~20
units prior to his OLT. Throughout his adult
course aminotransferases (AST, ALT) and
bilirubin were elevated (Figure 1). Viral
serologies for hepatitis B, hepatitis C and
human immunodeficiency virus were negative
and ferritin was 129 ng/mL.  In 2005, treatment
with hydroxyurea 1g daily was started and he
used occasional opioids as needed.  
In August 2006, 8 months prior to orthotopic
liver transplant, he developed jaundice.  His
total bilirubin was 14.0 ng/dL, alkaline phos-
phatase 614, AST 176, ALT 110, and ferritin 237
ng/mL.  Liver biopsy in November 2006 showed
severe cholestasis, bile ductular proliferation
and cirrhosis (Figure 2). RBC exchange trans-
fusions were begun and continued every 4-6
weeks to achieve Hgb S concentrations <30%.
One month prior to his transplant, he was
maintained on simple RBC transfusions to
maintain Hgb >7 g/dL.       
In March 2007 he was admitted to the
Intensive Care Unit with severe anemia, acute
renal insufficiency, and deepening jaundice.
Laboratory data included Hgb 5.8 g/dL, Hct
17.1, Hgb S 15.7%, bilirubin 46.5, alk phos 387,
AST 223, ALT 93, and creatinine 4.5. He was
evaluated and listed for OLT with a Model for
End-Stage Liver Disease score of 40. Fourteen
days later he underwent an orthotopic liver
transplantation from an ABO matched adult
cadaveric donor.      
The transplantation was accomplished with
minimal blood loss. During surgery the
patient was transfused with 3 units of packed
RBCs, 1000 mL of 5% albumin and 3 liters of
crystalloid. The donor graft appeared normal;
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the cold ischemia time was 9 hours and the
warm ischemia time was 28 minutes. The
graft liver was placed in a standard piggyback
fashion with bile duct-to-duct anastomosis.
The liver explant showed cirrhosis with
marked autolysis, and cholestasis with bile
duct proliferation.
The post-operative course was complicated
by seizures and acute respiratory distress,
which required intubation during the post-
operative course. His Hgb was maintained
throughout the hospital course between 7-10
and Hgb S <2% with RBC transfusions. His
urine output, lung function and mental status
improved gradually, and he was discharged on
the postoperative day 31 in stable condition.  
The patient received immunosuppression
with mycophenolate mofetil, prednisone, and
tacrolimus. The prednisone was gradually
tapered and he was maintained on mycophe-
nolate mofetil and tacrolimus long-term. He
was maintained on 2 units RBC transfusions
every 4 weeks for target of Hgb of 10 g/dL for
one year. His AST and ALT have decreased
since the transplantation and liver function
has improved (Figures 1 and 2). He had no
post-operative sickle cell related complications
and 12 months after transplant RBC treat-
ments were stopped and he has been main-
tained on hydroxyurea.     
Discussion and Conclusions
SCIC is a highly fatal complication of sickle
cell disease. It has been documented that
intrahepatic cholestasis has a mortality of 40%
without the use of exchange transfusions.6,8 In
a review of 26 reported patients, Khurshid et
al. found that with exchange transfusion ther-
apy, the mortality from intrahepatic cholesta-
sis was 17% suggesting that it remains a
potentially fatal condition despite medical
treatment.7 In the patient reported here, RBC
exchange transfusion therapy every 4-6 weeks
for 3 months prior to liver transplantation was
successful to maintain a target Hgb S <30%,
but his liver function continued to decline. In
these patients, OLT becomes the only thera-
peutic option.
There have been few reported cases of OLT
in patients with sickle cell disease. A review of
the literature identified 10 adult and 5 children
with sickle cell disease (Table 1).2,5,6,9-17 In 6 of
the 10 reported adult cases, liver transplanta-
tion resulted in improved function and long-
term survival. Of the 4 that resulted in post-
OLT death, 2 were from causes unrelated to the
OLT or liver dysfunction (1 from intracranial
bleed 5 months post-op due to pre-existing vas-
cular anomaly and 1 from pulmonary embolism
22 months post-op). Nevertheless, sickle cell
related allograft complications occurred in 5 of
the 6 survived cases. Among 3 of 5 pediatric
cases, transplantation was successful.  
There are a number of challenges in consid-
ering OLT for sickle cell disease patients. First,
surgery itself presents as a procedure with
high morbidity and mortality risk. Early studies
show on average 10% mortality and >50% risk
of perioperative complications in sickle cell
disease patients undergoing a variety of surgi-
cal procedures but this can be reduced sub-
stantially with preoperative RBC transfu-
sion.17,18 Sickle cell related complications such
as intrahepatic sickling and vaso-occlusion
can recur in the graft causing deterioration in
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Figure 1. Aspartate aminotransferase/alanine aminotransferase (AST/ALT) (IU/L), and
bilirubin (mg/dL).
Figure 2. Liver biopsy in 2006 - severe cholestasis with fibrosis, ductular proliferation and
cirrhosis (Haematoxilyn and Eosin stain).
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function.5,12,14,15,17 Preoperative transfusion
therapy can be used to mitigate the post-op
complications. The National Preoperative
Transfusion Study evaluating the risk of chole-
cystectomy in SCD patients found that post-op
complications of SCD were higher in the non-
transfused than the transfused group.19 Our
patient was heavily transfused in preparation
for his liver transplant to decrease sickle cell
related complications. Notably, post-operative
transfusion therapy has been utilized by a
majority of the OLT cases to reduce risk of
long-term graft sickle cell related complica-
tions. Nevertheless, the intensity and duration
of transfusion therapy is not well defined and
varies between studies. The experience with
our patient suggests that aggressive RBC
transfusion is warranted; however, chronic
transfusion therapy places patients at risk for
transfusion related iron overload.  
Liver failure secondary to sickle cell intra-
heptic cholestasis is a complicated clinical
problem and in our case, medical management
with hydroxyurea, and aggressive RBC trans-
fusions were not able to reverse his declining
liver function. The current experience and role
for OLT in sickle cell disease patients is limit-
ed. This case had a successful outcome with
OLT plus RBC support. OLT should be consid-
ered as treatment option for sickle cell disease
patients with advanced liver failure.  
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